Oramed Receives Patent Allowance on Core Oral GLP-1 Technology in Israel

Oramed Pharmaceuticals

announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology. Exenatide, a GLP-1 analog, is currently only marketed in injectable form, and is indicated for the treatment of Type 2 diabetes. Exenatide has an excellent safety profile and a plethora of positive medicinal effects including weight loss and improved pancreatic cell function.